Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell

被引:100
作者
Taylor, PA
Friedman, TM
Korngold, R
Noelle, RJ
Blazar, BR
机构
[1] Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Pediat, Div Bone Marrow Transplantat, Minneapolis, MN 55455 USA
[3] Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, Philadelphia, PA 19107 USA
[4] Dartmouth Hitchcock Med Ctr, Dept Microbiol, Hanover, NH USA
关键词
D O I
10.1182/blood.V99.12.4601
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We previously reported that ex vivo blockade of the CD40:CD40L costimulatory pathway in primary mixed lymphocyte reaction cultures resulted in profound in vitro secondary hyporesponsiveness and 30-fold or greater protection from graft-versus-host-disease (GVHD) lethality. Present studies demonstrate that tolerance induction via costimulatory blockade also results in the generation of a potent immunoregulatory cell that inhibits both naive and primed alloresponses. The immunoregulatory capacity was dependent upon cell-to-cell contact that prevented the full activation of the naive or primed cells. The inhibitory effect of tolerized cells did not preclude the response of naive T cells to nominal protein antigen if antigen was present at high concentration. However, under suboptimal antigen concentration, nonspecific inhibition of responses occurred. The tolerized regulatory cell population maintained a polyclonal T-cell receptor Vbeta repertoire that was broader than in control primed cultures. These data, the first to demonstrate that tolerance induction via CD40:CD40L costimulatory blockade results in potent regulatory function, are relevant to bone-marrow and solid-organ transplantation. The generation of potent immunoregulatory capacity during tolerization via CD40:CD40L blockade provides a fail-safe mechanism to control alloreactive T cells that may have escaped tolerization. These potent regulatory cells may be clinically exploitable for the treatment and prevention of GVHD or autoimmunity. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:4601 / 4609
页数:9
相关论文
共 21 条
[21]  
Zeller JC, 1999, J IMMUNOL, V163, P3684